We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$18.8M
Cap. Flow %
-0.51%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX icon
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 97.32%
2 Technology 1.61%
3 Financials 0.8%
4 Consumer Discretionary 0.14%
5 Miscellaneous 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$53.2M 1.44%
568,000
-13,000
-2% -$1.2M
2019 Q4
6 quarters
BPMC icon
27
DELISTED
Blueprint Medicines
BPMC
$49.5M 1.34%
563,200
+17,200
+3% +$1.58M
2020 Q4
2 quarters
NTRA icon
28
Natera
NTRA
$58.3B
$49.5M 1.34%
436,000
+40,400
+10% +$4.13M
2020 Q3
3 quarters
SHC icon
29
Sotera Health
SHC
$5.16B
$46.3M 1.25%
1,910,000
+749,000
+65% +$18.4M
2020 Q4
2 quarters
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$45M 1.22%
358,500
+35,700
+11% +$4.5M
2020 Q4
2 quarters
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.27B
$43.4M 1.17%
2,070,000
+598,000
+41% +$12.3M
2021 Q1
1 quarter
UTHR icon
32
United Therapeutics
UTHR
$23.2B
$42.4M 1.15%
+236,400
New +$45M
2021 Q2
0 quarters
BBIO icon
33
BridgeBio Pharma
BBIO
$13.1B
$41M 1.11%
673,400
-141,700
-17% -$8.09M
2021 Q1
1 quarter
ATEC icon
34
Alphatec Holdings
ATEC
$1.69B
$40.2M 1.09%
2,621,000
+287,000
+12% +$4.43M
2020 Q4
2 quarters
TRIL
35
DELISTED
Trillium Therapeutics Inc.
TRIL
$39.8M 1.08%
4,105,000
+90,000
+2% +$847K
2020 Q3
3 quarters
CYT
36
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$38.7M 1.05%
+1,808,394
New +$33.9M
2021 Q2
0 quarters
CMPS icon
37
Compass Pathways
CMPS
$1.61B
$38.1M 1.03%
+1,000,000
New +$35.7M
2021 Q2
0 quarters
CAH icon
38
Cardinal Health
CAH
$58.7B
$37.3M 1.01%
654,200
-808,800
-55% -$47.3M
2020 Q4
2 quarters
KDMN
39
DELISTED
Kadmon Holdings, Inc.
KDMN
$36M 0.97%
9,294,600
-249,600
-3% -$968K
2019 Q4
6 quarters
DVAX icon
40
DELISTED
Dynavax Technologies
DVAX
$33.5M 0.91%
3,400,000
-100,000
-3% -$909K
2019 Q4
6 quarters
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$31.3B
$33.1M 0.89%
195,000
-232,969
-54% -$34.1M
2021 Q1
1 quarter
INSM icon
42
Insmed
INSM
$21.7B
$32.7M 0.88%
+1,150,050
New +$34.1M
2021 Q2
0 quarters
SPNE
43
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$31.3M 0.85%
+1,524,998
New +$31.4M
2021 Q2
0 quarters
LFST icon
44
Lifestance Health
LFST
$4.7B
$30.6M 0.83%
+1,100,000
New +$29.1M
2021 Q2
0 quarters
IPSC icon
45
Century Therapeutics
IPSC
$272M
$29.4M 0.8%
+1,003,522
New +$25.5M
2021 Q2
0 quarters
LEGN icon
46
Legend Biotech
LEGN
$3.85B
$25.7M 0.69%
+625,000
New +$21.2M
2021 Q2
0 quarters
IMCR icon
47
Immunocore
IMCR
$1.52B
$23.5M 0.63%
601,000
+51,000
+9% +$1.97M
2021 Q1
1 quarter
ACET icon
48
Adicet Bio
ACET
$48.1M
$23.2M 0.63%
140,656
+1,281
+0.9% +$261K
2021 Q1
1 quarter
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$3.4B
$22.9M 0.62%
+940,000
New +$21.2M
2021 Q2
0 quarters
LENZ icon
50
LENZ Therapeutics
LENZ
$112M
$22.6M 0.61%
+105,071
New +$18.3M
2021 Q2
0 quarters
1
2
3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.